SecBot SecBot
SECBOTREPLAY Home › Report › SNY

SNY · Sanofi reported positive phase 3 results for Nexviazyme…

Sanofi · 6-K filed Jul 7, 2026 at 09:02 ET

At the news

BULLISHIMPACT 5/10

6-K filed Jul 7, 2026 at 09:02 ET

Sanofi reported positive phase 3 results for Nexviazyme (avalglucosidase alfa) in infantile-onset Pompe disease (IOPD). The Baby-COMET study met all primary and secondary endpoints, including the primary endpoint of participants alive and free of invasive ventilation at 52 weeks. Sanofi intends to file for a US label extension in H2 2026, which could modestly expand the drug's addressable market. The safety profile was consistent with the established profile.

  • Nexviazyme met its primary endpoint in the Baby-COMET phase 3 study: proportion of participants alive and free of invasive ventilation at 52 weeks.
  • All secondary endpoints were met, including proportion alive and free of invasive ventilation at 12 and 18 months of age.
  • Sanofi plans to submit the data for a US label extension in the second half of 2026.
  • No serious treatment-related adverse events, deaths, or discontinuations were reported.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access